Penn University 628x158

To complete the JPS TAP Trial survey, click here.

Trauma is the leading cause of death in those under the age of 45. The most common cause of preventable death after injury is bleeding, which is often accompanied by clotting factor abnormalities.

Kcentra® (or 4-factor prothrombin complex concentrate) is a Food and Drug Administration (FDA) approved product that contains clotting factors. It is currently used to reverse the effects of medications given to “thin” the blood in patients, when such patients experience bleeding and/or require surgery.

There is evidence that Kcentra® may be beneficial (reduce the chance of dying) in injured patients who are not on blood-thinning medication. The TAP trial is a research trial to see whether Kcentra reduces the chances of injured people dying from their injuries. The aim of the Trauma and PCC (TAP) trial is to formally evaluate the effectiveness of Kcentra®, in addition to all standard care, in injured patients predicted to require a large volume blood transfusion. Standard care typically involves the transfusion of different types of blood products, and the use of medications to help the blood clot (as well as surgery, to stop the bleeding). Because Kcentra must be administered quickly to possibly help patients and most patients cannot consent to a study soon after a serious injury, most patients will be enrolled without their consent.

TAP is one of the largest trauma trials ever conducted. It will involve up to 8,000 patients, across 140 hospitals (around 100 of them in the United States, the remainder in a small number of other countries).

Do you have any comments you would like to tell the researchers about this study?  We would value your feedback via the link below.  Your feedback will remain confidential.